唯一登记、甲羧除草醚、双重作用：安道麦在葡萄牙推出新型除草剂SONAVIO®
世界农化网中文网报道：安道麦近日在葡萄牙推出新型除草剂SONAVIO®（活性成分：甲羧除草醚），该产品专为工业番茄种植中的移栽前除草设计，是目前葡萄牙市场上唯一获得该用途登记的除草剂产品。
Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine
Why it matters: The deal is a fresh validation point for Antares, a Scorpion Therapeutics spinout built around the idea that some “undruggable” cancer targets can be reached with better chemistry, screening and computational tools.
BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development
SAN DIEGO — The U.S. Food and Drug Administration (FDA) is in the middle of a cultural and operational shift that goes beyond leadership changes. U.S.–China biotechnology competition is driving discussions around regulatory reform in the U.S. where traditional paradigms are being reviewed and reconsidered, particularly for rare diseases. And patient perspectives need to be a more integral part of the drug development continuum.
富美实1.14亿美元出售研发总部地产，售后回租保障Stine中心持续运营
世界农化网中文网报道：富美实（FMC）公司近日宣布，已就出售其位于特拉华州纽瓦克的地产签署框架协议，交易总价约为1.14亿美元。此次出售的物业为FMC全球研发总部所在地——Stine研究中心。
Leyden Labs adds €40m for intranasal flu prevention
Why it matters: The financing adds further momentum to one of Europe’s more closely watched respiratory virus prevention companies, as investors continue to back antibody-based alternatives and complements to seasonal vaccines.
Scaling Plant-Based Waste: Vertoro Closes €17 Million Series B Round
By Staff Writer, Global AgInvesting MediaThe landscape of sustainable agribusiness and advanced biofuels is shifting. In the climate tech sector, renewable oil company Vertoro has announced the first closing of its €17 million Series B funding round. As noted by OneStop ESG, the round consists of €10 million in newly contributed capital and €7 million in converted loan notes.
Dedication To Applied Research Leaves Lasting Legacy
June 2026, AU: After 23 years driving improvements for Australian grain growers, Nick Poole leaves a legacy that will re…
InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms
Credit: FatCamera/Getty Images Lonza and InduPro signed a licensing agreement to support the advancement of innovative antibody–drug conjugate (ADC) therapies. According to Lonza officials, the company, through one of its affiliated companies, will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect®, HydraSpace® and linker-payload technologies. The technologies, which will be applied to the development of ADCs targeting up to two oncology antigens, are intended to support the advancement of highly targeted cancer therapies.
GRDC says APVMA Decision May Instigate Further Research Into Use Patterns
June 2026, AU: The Grains Research and Development Corporation (GRDC) says the decision by the Australian Pesticides and…
Federal Court Rules Washington State Industrial Shellfish Aquaculture Operations Unlawful
June 2026, WA: Yesterday, the U.S. District Court for the Western District of Washington sided with Center for…